DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on July 19, 2006; DOI: 10.1124/dmd.106.010199


0090-9556/06/3410-1779-1785$20.00
DMD 34:1779-1785, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.106.010199v1
34/10/1779    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Casabar, R. C. T.
Right arrow Articles by Rose, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Casabar, R. C. T.
Right arrow Articles by Rose, R. L.

Metabolism of Endosulfan-{alpha} by Human Liver Microsomes and Its Utility as a Simultaneous in Vitro Probe for CYP2B6 and CYP3A4

Richard C. T. Casabar, Andrew D. Wallace, Ernest Hodgson, and Randy L. Rose1

Department of Environmental and Molecular Toxicology, North Carolina State University, Raleigh, North Carolina

Endosulfan-{alpha} is metabolized to a single metabolite, endosulfan sulfate, in pooled human liver microsomes (Km = 9.8 µM, Vmax = 178.5 pmol/mg/min). With the use of recombinant cytochrome P450 (P450) isoforms, we identified CYP2B6 (Km = 16.2 µM, Vmax = 11.4 nmol/nmol P450/min) and CYP3A4 (Km = 14.4 µM, Vmax = 1.3 nmol/nmol P450/min) as the primary enzymes catalyzing the metabolism of endosulfan-{alpha}, although CYP2B6 had an 8-fold higher intrinsic clearance rate (CLint = 0.70 µl/min/pmol P450) than CYP3A4 (CLint = 0.09 µl/min/pmol P450). Using 16 individual human liver microsomes (HLMs), a strong correlation was observed with endosulfan sulfate formation and S-mephenytoin N-demethylase activity of CYP2B6 (r2 = 0.79), whereas a moderate correlation with testosterone 6 ß-hydroxylase activity of CYP3A4 (r2 = 0.54) was observed. Ticlopidine (5 µM), a potent CYP2B6 inhibitor, and ketoconazole (10 µM), a selective CYP3A4 inhibitor, together inhibited approximately 90% of endosulfan-{alpha} metabolism in HLMs. Using six HLM samples, the percentage total normalized rate (% TNR) was calculated to estimate the contribution of each P450 in the total metabolism of endosulfan-{alpha}. In five of the six HLMs used, the percentage inhibition with ticlopidine and ketoconazole in the same incubation correlated with the combined % TNRs for CYP2B6 and CYP3A4. This study shows that endosulfan-{alpha} is metabolized by HLMs to a single metabolite, endosulfan sulfate, and that it has potential use, in combination with inhibitors, as an in vitro probe for CYP2B6 and 3A4 catalytic activities.


Address correspondence to: Ernest Hodgson, Department of Environmental and Molecular Toxicology, Box 7633, North Carolina State University, Raleigh, NC 27695. E-mail: ernest_hodgson{at}ncsu.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.